PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-552.87%
Negative operating income growth while CRVO is at 16.47%. Joel Greenblatt would press for urgent turnaround measures.
-675.86%
Negative net income growth while CRVO stands at 7.73%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-2175.00%
Negative EPS growth while CRVO is at 8.01%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-2175.00%
Negative diluted EPS growth while CRVO is at 8.01%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-66.67%
Share reduction while CRVO is at 0.31%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-66.67%
Reduced diluted shares while CRVO is at 0.31%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
18.86%
Positive OCF growth while CRVO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
18.86%
Positive FCF growth while CRVO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-262.10%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
43.72%
Debt growth of 43.72% while CRVO is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.